ADMA Biologics (NASDAQ:ADMA) Trading 3.5% Higher

ADMA Biologics, Inc. (NASDAQ:ADMA)’s share price was up 3.5% during mid-day trading on Tuesday . The stock traded as high as $6.19 and last traded at $6.19. Approximately 862,242 shares traded hands during trading, a decline of 67% from the average daily volume of 2,645,077 shares. The stock had previously closed at $5.98.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on ADMA shares. HC Wainwright restated a “buy” rating and set a $7.50 price objective (up from $6.00) on shares of ADMA Biologics in a research report on Tuesday, March 26th. Cantor Fitzgerald raised their price objective on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Finally, Mizuho raised their price objective on shares of ADMA Biologics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $7.88.

ADMA Biologics Stock Up 0.8 %

The business’s 50-day simple moving average is $5.91 and its two-hundred day simple moving average is $4.73. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.69 and a current ratio of 5.16.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The business had revenue of $73.90 million during the quarter, compared to analysts’ expectations of $73.50 million. As a group, equities research analysts predict that ADMA Biologics, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, Director Steve Elms sold 183,008 shares of ADMA Biologics stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $6.01, for a total value of $1,099,878.08. Following the completion of the transaction, the director now owns 2,577,387 shares in the company, valued at $15,490,095.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders sold 639,895 shares of company stock worth $3,927,169. Corporate insiders own 6.00% of the company’s stock.

Institutional Trading of ADMA Biologics

Institutional investors have recently modified their holdings of the stock. Virtu Financial LLC purchased a new stake in shares of ADMA Biologics during the 2nd quarter worth approximately $34,000. Envestnet Asset Management Inc. purchased a new stake in shares of ADMA Biologics during the 1st quarter worth approximately $35,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of ADMA Biologics during the 2nd quarter worth approximately $35,000. Stephens Consulting LLC purchased a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $36,000. Finally, Cerity Partners LLC acquired a new position in ADMA Biologics in the 2nd quarter valued at $37,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.